Innoviva (INVA) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Innoviva (INVA) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 22.4% versus a loss of 11.1%. Over five years, INVA leads with a +26.8% price change compared with +3.3% for STOK. Stoke Therapeutics is the larger company by market cap ($1.56 billion vs $1.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | STOK |
|---|---|---|
| Share price | $20.88 | $24.17 |
| Market cap | $1.51B | $1.56B |
| 1-day change | -0.85% | -0.51% |
| YTD return | +5.35% | -23.47% |
| 1-year return | +22.44% | -11.06% |
| 5-year return | +26.79% | +3.27% |
| P/E ratio (TTM) | 4.88 | — |
| Forward P/E | 9.45 | — |
| EPS (TTM) | $4.28 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.15 | $40.22 |
| 52-week low | $16.52 | $20.32 |
| Distance from 52-week high | -16.98% | -39.92% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +67.62% | +92.26% |
| Average volume | 819.96K | 852.03K |
| Shares outstanding | 72.25M | 64.53M |
| Employees | 159 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INVA has outperformed STOK by 33.5 percentage points over the past year.
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
INVA vs STOK FAQ
Which is bigger, Innoviva or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.56B compared with $1.51B for Innoviva (INVA).
Which stock has performed better over the past year, INVA or STOK?
INVA returned +22.44% over the past 12 months, compared with -11.06% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.